Sharekhan

Kilitch Drugs(I) Ltd

Wed 30/07/2025,15:15:50 | NSE : KILITCH

₹ 443.903.90 (0.89%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 445.00

Previous Close

₹ 440.00

Volume

3184

Mkt Cap ( Rs. Cr)

₹775.97

High

₹ 445.00

Low

₹ 443.90

52 Week High

₹ 500.00

52 Week Low

₹ 304.51

Book Value Per Share

₹ 144.30

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Kilitch Drugs(I) Ltd

Your Vote -

Buy

58.33%

Hold

8.33%

Sell

33.33%

58.33%

12 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

438.30

10

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

10

Option Chain

Analyzes market sentiment, predicts Kilitch Drugs(I) Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Kilitch Drugs(I) has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025

    19 Jul 2025, 7:02AM As of June 2025, 69.23% is owned by Indian Promoters and 30.77% by Public. <p align=justify> Top four Promoters holding highest number of shares of Ki
  • Kilitch Drugs(I) - Copy of Newspaper Publication

    18 Jul 2025, 2:48PM Kilitch Drugs (India) Limited has informed the Exchange about Copy of Newspaper Publication
  • Kilitch Drugs(I) - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    15 Jul 2025, 5:52PM Kilitch Drugs (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Kilitch Drugs(I) - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    15 Jul 2025, 5:57PM We hereby submit Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation, 2018 receive
  • Kilitch Drugs(I) - Updates

    12 Jul 2025, 5:52PM Kilitch Drugs (India) Limited has informed the Exchange regarding submission of Letter of Offer in connection with Proposed Rights Issue of the Fully
  • Kilitch Drugs(I) - Corporate Action-Outcome of Right issue

    12 Jul 2025, 5:33PM Submission of Letter of Offer in connection with Proposed Right Issue of the Fully Paid - up Equity shares of Kilitch Drugs (India) Limited in terms o
  • Kilitch Drugs(I) - Corrigendum To Outcome Of Board Meeting Held On July 12, 2025

    12 Jul 2025, 2:17PM Submission of Corrigendum of Outcome of Board meeting held on July 12, 2025
  • Kilitch Drugs(I) - Updates

    12 Jul 2025, 2:14PM Kilitch Drugs (India) Limited has informed the Exchange regarding 'Corrigendum to Outcome of Board Meeting held on July 12, 2025'.
  • Kilitch Drugs(I) - Board Meeting Outcome for Outcome Of Board Meeting Scheduled To Approve Issue Period And Letter Of Offer

    12 Jul 2025, 10:40AM Board meeting to approve issue period and letter of offer
  • Kilitch Drugs(I) - Rights Issue

    12 Jul 2025, 10:36AM Kilitch Drugs (India) Limited has informed the Exchange that Board of Directors at its meeting held on July 12, 2025, has decided to issue equity shar
  • Kilitch Drugs(I) - Record Date

    9 Jul 2025, 7:19PM Kilitch Drugs (India) Limited has informed the Exchange that Record date for the purpose of Rights is 15-Jul-2025.
  • Kilitch Drugs(I) - Intimation Of Record Date

    9 Jul 2025, 7:16PM Intimation of Record for the purpose of right issue
  • Kilitch Drugs(I) - Board Meeting Outcome for Outcome Of Board Meeting

    9 Jul 2025, 7:12PM Issue of equity shares of company on right issue basis
  • Kilitch Drugs(I) - Rights Issue

    9 Jul 2025, 7:09PM Kilitch Drugs (India) Limited has informed the Exchange that Board of Directors at its meeting held on July 09, 2025, has decided to issue equity shar
  • Kilitch Drugs(I) - Outcome of Board Meeting

    2 Jul 2025, 1:04PM Raising of funds by way of issue of equity shares of the Company on right issue basis
  • Kilitch Drugs(I) - Board Meeting Outcome for Outcome Of Board Meeting

    2 Jul 2025, 12:58PM Raising of Fund by way of issue of equity shares of the company on right issue basis
  • Kilitch Drugs(I) - Trading Window-XBRL

    29 Jun 2025, 2:41PM KILITCH DRUGS (INDIA) LIMITED has informed the Exchange about Closure of Trading Window
  • Kilitch Drugs(I) - Trading Window

    29 Jun 2025, 2:36PM Kilitch Drugs (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulat
  • Kilitch Drugs(I) - Board Meeting Intimation

    29 Jun 2025, 2:33PM KILITCH DRUGS (INDIA) LIMITED has informed the Exchange about Board Meeting to be held on 02-Jul-2025 to consider and approve Fund raising/Other busin
  • Kilitch Drugs(I) - Disclosure under SEBI Takeover Regulations

    25 Jun 2025, 7:38PM Mukund Mehta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acqu
  • Kilitch Drugs(I) - Press Release

    22 May 2025, 5:11PM Kilitch Drugs (India) Limited has informed the Exchange regarding a press release dated May 22, 2025, titled ""Q4FY25 Financial Results"".
  • Kilitch Drugs(I) - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    22 May 2025, 5:14PM We are enclosing herewith the press release relating to Financial Results for Q4FY25
  • Kilitch Drugs(I) - Copy of Newspaper Publication

    21 May 2025, 3:59PM Kilitch Drugs (India) Limited has informed the Exchange about Copy of Newspaper Publication
  • Kilitch Drugs(I) - Financial Results

    19 May 2025, 9:32PM Approved and Considered audited standalone and consolidated financial results for the quarter ended 31st March, 2025
  • Kilitch Drugs(I) Q4 net profit zooms 212.36% at Rs 11.37 cr

    19 May 2025, 9:21PM The company reported standalone net profit of Rs 11.37 crore for the quarter ended March 31, 2025 as compared to Rs 3.64 crore in the same period last
  • Kilitch Drugs(I) - Board Meeting Outcome for Outcome Of Board Meeting

    19 May 2025, 9:21PM Outcome of Board Meeting
  • Kilitch Drugs(I) - Outcome of Board Meeting

    19 May 2025, 9:19PM Kilitch Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
  • Kilitch Drugs(I) - Board Meeting Intimation

    13 May 2025, 2:52PM KILITCH DRUGS (INDIA) LIMITED has informed the Exchange about Board Meeting to be held on 19-May-2025 to inter-alia consider and approve the Audited F
  • Kilitch Drugs(I) - Board Meeting Intimation for Considering And Approving Standalone And Consolidated Quarterly Financial Res

    13 May 2025, 2:47PM Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 ,inter alia, to consider

Key fundamentals

Evaluate the intrinsic value of Kilitch Drugs(I) Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 302.0384 254.2407 217.7951 198.366 177.6409
Liabilities 302.0384 254.2407 217.7951 198.366 177.6409
Equity 16.0823 16.0823 15.5823 15.5823 15.4945
Gross Profit 30.8373 20.3169 17.1734 10.9961 5.2094
Net Profit 31.1569 17.5738 15.7173 10.5277 6.1554
Cash From Operating Activities 15.2328 -1.1932 6.0976 5.205 6.1254
NPM(%) 17.15 13.35 13.34 10.01 8.79
Revenue 181.5873 131.599 117.7835 105.1598 70.0168
Expenses 150.75 111.2821 100.6101 94.1637 64.8074
ROE(%) 12.35 6.96 6.23 4.17 2.44

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
20 Sep 2019 0.5 5 0 172.95
18 Sep 2018 0.5 5 0 89.1
24 Sep 2012 30 300 0 69.7
18 Aug 2011 1 10 0 71.15

Peers

Other companies within the same industry or sector that are comparable to Kilitch Drugs(I) Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 895.40 -1.33 29.71 253.91 301.39 0.56
Lotus Eye Hospital and Institute Ltd 72.74 -1.49 207.83 925.23 3.55 0.00
Vaishali Pharma Ltd 12.43 0.89 207.17 476.90 3.13 0.00
Astec Lifesciences Ltd 864.50 -0.98 0.00 872.51 -601.21 0.00

Company Info

M/s Kilitch Drugs (India) ltd was incorporated on 12th May, 1992 with the Registrar of Companies, Maharashtra at Bombay as a public limited company and obtained certificate for commencement of business dated 26-05-92. The company went Public in February 1994 for setting up a pharmaceutical formulation plant to manufacture pharmaceutical products in the form of tablets, capsules, liquid orals, ointments, creams and injectables. The company could not commence its manufacturing activities as planned in the Public Issue on account of delay in completion of building. Till date, the company has not commenced any manufacturing activities. The land and building is now completed and in order to have the benefit of its capacity, the company is planning this rights issue for expanding its injectable capacity from 30,000 ltrs. to 75,000 Itrs. Due to delay in implementation of project, the company could not come out with its own production till date and therefore the company is presently trading in pharmaceutical formulations like tablets, capsules, liquid orals, ointments, creams and injectables. The trading turnover of the company for the year 1994-95 was Rs.550.50 Lacs. 2008 -Board recommends final dividend of 10%. 2009 -The Company got a GOLD AWARD for Quality Excellence. 2010 -Listing of Equity Shares at NSE. 2011 2015 -Kilitch Drugs entered joint venture with local firm in Ethopia 2021 -Kilitch Drugs starts production of Cephalosporins Injectables at Ethiopia Plant' dated 26th July 2021.

M/s Kilitch Drugs (India) ltd was incorporated on 12th May, 1992 with the Registrar of Companies, Maharashtra at Bombay as a public limited company and obtained certificate for commencement of business dated 26-05-92. The company went Public in February 1994 for setting up a pharmaceutical formulation plant to manufacture pharmaceutical products in the form of tablets, capsules, liquid orals, ointments, creams and injectables. The company could not commence its manufacturing activities as planned in the Public Issue on account of delay in completion of building. Till date, the company has not commenced any manufacturing activities. The land and building is now completed and in order to have the benefit of its capacity, the company is planning this rights issue for expanding its injectable capacity from 30,000 ltrs. to 75,000 Itrs. Due to delay in implementation of project, the company could not come out with its own production till date and therefore the company is presently trading in pharmaceutical formulations like tablets, capsules, liquid orals, ointments, creams and injectables. The trading turnover of the company for the year 1994-95 was Rs.550.50 Lacs. 2008 -Board recommends final dividend of 10%. 2009 -The Company got a GOLD AWARD for Quality Excellence. 2010 -Listing of Equity Shares at NSE. 2011 2015 -Kilitch Drugs entered joint venture with local firm in Ethopia 2021 -Kilitch Drugs starts production of Cephalosporins Injectables at Ethiopia Plant' dated 26th July 2021.

Read More

Parent Organisation

Kilitch Drugs(I) Ltd.

Founded

12/05/1992

Managing Director

Mr.Mukund P Mehta

NSE Symbol

KILITCHBE

FAQ

The current price of Kilitch Drugs(I) Ltd is ₹ 443.90.

The 52-week high for Kilitch Drugs(I) Ltd is ₹ 445.00 and the 52-week low is ₹ 443.90.

The market capitalization of Kilitch Drugs(I) Ltd is currently ₹ 775.97. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Kilitch Drugs(I) Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Kilitch Drugs(I) Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Kilitch Drugs(I) Ltd shares.

The CEO of Kilitch Drugs(I) Ltd is Mr.Mukund P Mehta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT